F
F Hilton
Researcher at Pfizer
Publications - 4
Citations - 502
F Hilton is an academic researcher from Pfizer. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 480 citations.
Papers
More filters
Journal ArticleDOI
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial
B J Kullberg,Jack D. Sobel,Markus Ruhnke,Peter G. Pappas,Claudio Viscoli,John H. Rex,John D. Cleary,E Rubinstein,L W P Church,J M Brown,Haran T. Schlamm,I T Oborska,F Hilton,Michael R. Hodges +13 more
TL;DR: Voriconazole was as effective as the regimen of amphotericin B followed by fluconazole in the treatment of candidaemia in non-neutropenic patients, and with fewer toxic effects.
Journal ArticleDOI
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
Rubi K. Li,Eriko Tokunaga,Hryhoriy Adamchuk,Vladimir Vladimirov,Eduardo Yanez,Keun Seok Lee,Igor Bondarenko,Alicia M Vana,F Hilton,K. Ishikawa,Kentaro Tajima,Oleg Lipatov +11 more
TL;DR: In this paper , the authors compared PF-05280014 and trastuzumab-EU, each plus paclitaxel, as first-line treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer in a phase III study.
Journal ArticleDOI
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study
Rubi K. Li,Eriko Tokunaga,Hryhoriy Adamchuk,Vladimir Vladimirov,Eduardo Yanez,Keun Seok Lee,Igor Bondarenko,Alicia M Vana,F Hilton,K. Ishikawa,Kentaro Tajima,Oleg Lipatov +11 more
TL;DR: In this paper , the authors compared PF-05280014 and trastuzumab-EU, each plus paclitaxel, as first-line treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer in a phase III study.
Journal ArticleDOI
Evaluation of weight gain and overall survival of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy.
TL;DR: In this pooled analysis, weight gain during treatment with first-line platinum-based chemotherapy was associated with a significantly reduced risk of death in patients with advanced NSCLC, independent of tumor response defined by RECIST criteria.